| A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder (NCT02636842) | Alkermes, Inc. | 2015-12-01 |
| Development of a Mobile System for Self-management of Schizophrenia (SOS) (NCT01969500) | Dartmouth-Hitchcock Medical Center | 2015-11-01 |
| Modified Psychodynamic Psychotherapy for Patients With Schizophrenia (NCT02576613) | Charite University, Berlin, Germany | 2015-10-01 |
| RISE (Rehabilitation Intervention for People With Schizophrenia in Ethiopia) (NCT02160249) | London School of Hygiene and Tropical Medicine | 2015-09-01 |
| Comparison of E-health vs. In-person Multi-Family Group (MFG) (NCT02032680) | VA Office of Research and Development | 2015-08-19 |
| Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders (NCT02930005) | The University of Texas Health Science Center, Houston | 2015-08-07 |
| Evaluating the Efficacy of a Late-Life Schizophrenia Integrated Care Pathway to Treat Acute Psychotic Symptoms (NCT02529163) | Centre for Addiction and Mental Health | 2015-08-01 |
| Building Employment Skills Through Therapy for Veterans (NCT01992913) | VA Office of Research and Development | 2015-06-12 |
| Comparing Mobile Health (mHealth) and Clinic-Based Self-Management Interventions for Serious Mental Illness (NCT02421965) | Dartmouth-Hitchcock Medical Center | 2015-06-01 |
| OnTrack>An Online Role-Playing Game: A Small Business Innovation Research (SBIR) Grant (NCT02415764) | Center for Social Innovation, Massachusetts | 2015-06-01 |
| STimulation to Improve Auditory haLLucinations (NCT02360228) | University of North Carolina, Chapel Hill | 2015-05-01 |
| Exercise and Cognitive Training (NCT02326389) | Boston University Charles River Campus | 2015-05-01 |
| A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry (NCT02462473) | Janssen Research & Development, LLC | 2015-05-01 |
| A Pharmacokinetic Study of Paliperidone ER (NCT02433717) | National Taiwan University Hospital | 2015-04-01 |
| A New Paradigm for Illness Monitoring and Relapse Prevention in Schizophrenia (NCT01952041) | Dartmouth-Hitchcock Medical Center | 2015-03-13 |
| Task Sharing for the Care of Severe Mental Disorders in a Low-income Country (NCT02308956) | University of Cape Town | 2015-03-01 |
| Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia (NCT02197286) | NYU Langone Health | 2015-02-01 |
| Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia (NCT02411526) | Zogenix, Inc. | 2015-02-01 |
| Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients (NCT02188121) | Mclean Hospital | 2015-02-01 |
| Minocycline Augmentation to Clozapine (NCT02124811) | Emory University | 2015-02-01 |
| Self-Management Training and Automated Telehealth to Improve SMI Health Outcomes (NCT02188732) | Dartmouth-Hitchcock Medical Center | 2015-01-01 |
| Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia (NCT02069392) | University of Maryland, Baltimore | 2015-01-01 |
| Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia (NCT02234752) | Sheppard Pratt Health System | 2014-09-01 |
| Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia (NCT02417142) | University of Massachusetts, Worcester | 2014-09-01 |
| Magnesium Variations and Cardiometabolic Risk in Patients With Antipsychotic Drugs (NCT02986490) | University Hospital, Montpellier | 2014-09-01 |
| Bioavailability of LY03004 and Risperdal® Consta® (NCT02091388) | Luye Pharma Group Ltd. | 2014-09-01 |
| Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia (NCT02237235) | Northwestern University | 2014-08-01 |
| Prediction of Relapse in Schizophrenia/Schizoaffective Disorder With Smartphones and On-body Sensors (NCT02224430) | University of Alabama at Birmingham | 2014-08-01 |
| Perceptual Deficits in Schizophrenia (NCT02337439) | VA Connecticut Healthcare System | 2014-08-01 |
| Cognitive Remediation Therapy Within a Secure Forensic Setting (NCT02360813) | Central Mental Hospital | 2014-08-01 |
| Prednisolone Addition for Patients With Recent-onset Psychotic Disorder (NCT02949232) | UMC Utrecht | 2014-07-01 |
| Electroconvulsive Therapy in Clozapine-resistant Schizophrenia (NCT02159001) | Niuvanniemi Hospital | 2014-06-01 |
| A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and Homelessness (NCT02085447) | University Hospitals Cleveland Medical Center | 2014-05-01 |
| Integrated Metacognitive Therapy in First Episode Psychosis (NCT02131116) | Indiana University | 2014-05-01 |
| rTMS in First Episode Psychosis (NCT02131129) | Indiana University | 2014-04-30 |
| Psychosocial Intervention to Reduce Self-stigma and Improve Quality of Life Among People With Mental Illness in Chile (NCT03197168) | University of Chile | 2014-03-01 |
| D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions (NCT01981759) | NYU Langone Health | 2014-02-01 |
| Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia (NCT02034474) | New York State Psychiatric Institute | 2014-02-01 |
| Pilot-trial of Emotion-focused Cognitive Behavior Therapy for Patients With Schizophrenia (NCT02787122) | Philipps University Marburg | 2014-01-01 |
| Glutamate, Brain Connectivity and Duration of Untreated Psychosis (NCT02034253) | University of Alabama at Birmingham | 2014-01-01 |
| Oxytocin and CBSST for People With Schizophrenia (NCT01752712) | University of Maryland, Baltimore | 2014-01-01 |
| Transcranial Current Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia (NCT01963676) | University of North Carolina, Chapel Hill | 2014-01-01 |
| Measuring the Effect of Remote Monitoring of Treatment Adherence on the Risk of Re-admission of Ambulatory Schizophrenic Patients (NCT01729572) | Shalvata Mental Health Center | 2014-01-01 |
| RCT of Methotrexate Added to Treatment As Usual in Schizophrenia (NCT02074319) | Pakistan Institute of Living and Learning | 2013-12-01 |
| Enhancing Cognitive Training Through Exercise After a First Schizophrenia Episode (NCT02267070) | University of California, Los Angeles | 2013-11-01 |
| Simvastatin Addition for Patients With Recent-onset Schizophrenia (NCT01999309) | Iris Sommer | 2013-10-01 |
| Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations (NCT02149823) | Maria de las Mercedes Perez Rodriguez | 2013-09-01 |
| Targeted Self-Management for Epilepsy and Serious Mental Illness (TIME) (NCT01992393) | Case Western Reserve University | 2013-09-01 |
| Neuroendocrine and Immune Response to Stress in Schizophrenia (NCT01975584) | University of Maryland, Baltimore | 2013-09-01 |
| Personalized and Scalable Cognitive Remediation Approaches (NCT01945333) | New York State Psychiatric Institute | 2013-09-01 |
| rTMS for Working Memory Deficits in Schizophrenia (NCT01880255) | Centre for Addiction and Mental Health | 2013-06-01 |
| Effectiveness of Adherence Therapy for Schizophrenia (NCT01780116) | The Hong Kong Polytechnic University | 2013-05-01 |
| Omega-3 Dietary Supplements in Schizophrenia (NCT01786239) | Delbert Robinson | 2013-05-01 |
| Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths (NCT01788774) | Rovi Pharmaceuticals Laboratories | 2013-04-01 |
| Improving Care and Reducing Cost Study (NCT02364544) | Northwell Health | 2013-04-01 |
| Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia (NCT01793935) | K.N. Roy Chengappa | 2013-04-01 |
| Antipsychotic Effects on Brain Function in Schizophrenia (NCT01913327) | University of California, San Francisco | 2013-04-01 |
| Navigated αTMS in Treatment-resistant Schizophrenia (NCT01941251) | Niuvanniemi Hospital | 2013-03-21 |
| Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder (NCT02055287) | Luye Pharma Group Ltd. | 2013-03-01 |
| Efficacy of Repetitive Transcranial Magnetic Stimulation in the Prevention of Relapse of Schizoaffective (NCT02221635) | Xijing Hospital | 2013-03-01 |
| Lurasidone Effects on Tissue Glutamate in Schizophrenia (NCT02199743) | University of Texas Southwestern Medical Center | 2013-02-01 |
| Adherence in Patients Admitted to a Psychiatric Unit for Acute Psychosis: an Analysis of Serum Levels of Antipsychotics. (NCT01786369) | Northwell Health | 2013-02-01 |
| Valacyclovir Augmentation for Cognitive and Functional Remediation in Schizophrenia (NCT01794897) | University of Pittsburgh | 2013-02-01 |
| Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH) (NCT01822418) | Central Institute of Mental Health, Mannheim | 2013-01-01 |
| Contrasting Group Therapy Methods for Psychosis (NCT01764568) | University of British Columbia | 2013-01-01 |
| Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents (NCT01731119) | University of North Carolina, Chapel Hill | 2012-12-01 |
| Lifestyle Intervention for Diabetes and Weight Management in Psychosis (NCT01828931) | Centre for Addiction and Mental Health | 2012-12-01 |
| Kuvan in People With Schizophrenia and Schizoaffective Disorder (NCT01706965) | New York State Psychiatric Institute | 2012-10-01 |
| Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder (NCT01658150) | Icahn School of Medicine at Mount Sinai | 2012-09-01 |
| Brain Imaging, Cognitive Enhancement and Early Schizophrenia (NCT01561859) | Beth Israel Deaconess Medical Center | 2012-06-01 |
| PTSD (PostTraumatic Stress Disorder) Services for Veterans With SMI (Severe Mental Illness) (NCT01542229) | VA Office of Research and Development | 2012-05-03 |
| Antipsychotics and Risk of Hyperglycemic Emergencies (NCT02582736) | Canadian Network for Observational Drug Effect Studies, CNODES | 2012-04-01 |
| Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia (NCT01929889) | Northwestern University | 2012-04-01 |
| Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia (NCT02137993) | HK inno.N Corporation | 2012-03-01 |
| POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia (NCT01450514) | PharmaNeuroBoost N.V. | 2012-03-01 |
| Magnetic Seizure Therapy (MST) for Treatment Resistant Depression, Schizophrenia, and Obsessive Compulsive Disorder (NCT01596608) | Centre for Addiction and Mental Health | 2012-02-01 |
| RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder (NCT01490086) | Reviva Pharmaceuticals | 2011-12-01 |
| Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders (NCT01487668) | VA Office of Research and Development | 2011-12-01 |
| Social Cognition in Longstanding Psychosis (NCT01624831) | University of Arizona | 2011-11-01 |
| Reducing Internalized Stigma in People With Serious Mental Illness (NCT01259427) | VA Office of Research and Development | 2011-10-01 |
| Nicotinic Receptors and Schizophrenia (NCT01400477) | University of Colorado, Denver | 2011-07-01 |
| Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia (NCT01394471) | University of North Carolina, Chapel Hill | 2011-07-01 |
| Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder (NCT01423916) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2011-07-01 |
| Brain Health and Exercise in Schizophrenia (NCT01392885) | BC Mental Health and Addictions Research Institute | 2011-07-01 |
| L-arginine add-on Therapy in Patients With Schizophrenia (NCT02398279) | Hacettepe University | 2011-06-01 |
| Salsalate as an Adjunctive Treatment for Patients With Schizophrenia (NCT01578486) | University of Massachusetts, Worcester | 2011-06-01 |
| The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia (NCT01339858) | Indiana University | 2011-05-01 |
| Optimization of Treatment and Management of Schizophrenia in Europe (NCT01248195) | Rene Kahn | 2011-05-01 |
| Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): Substudy Site Copenhagen (NCT01555814) | Birte Glenthoj | 2011-05-01 |
| Selective Estrogen Receptor Modulators for Women of Child-bearing Age With Schizophrenia (NCT02354001) | The Alfred | 2011-04-01 |
| Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders (NCT01519557) | New York State Psychiatric Institute | 2011-04-01 |
| Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective Disorder (NCT01320982) | Sheba Medical Center | 2011-03-01 |
| A Comparison of Long-acting Injectable Medications for Schizophrenia (NCT01136772) | New York State Psychiatric Institute | 2011-03-01 |
| Raloxifene in Treatment of Schizophrenia and Schizoaffective Disorder (NCT01280305) | Sheba Medical Center | 2011-03-01 |
| Pregnenolone and L-theanine Augmentation in the Treatment for Schizophrenia and Schizoaffective Disorders (NCT01831986) | Sha'ar Menashe Mental Health Center | 2011-01-01 |
| Brain Circuits in Schizophrenia and Smoking (NCT01425684) | University of Maryland, Baltimore | 2010-12-20 |
| Neural Oscillations as Genetic and Functional Biomarkers in Normal and Disease States (NCT01425671) | University of Maryland, Baltimore | 2010-11-30 |
| The Antiatherogenic Properties of HDL in Psychiatric Patients With and Without Antipsychotic Therapy (NCT01215383) | Ziv Hospital | 2010-11-01 |
| An Epidemiological Study to Assess the Psychosocial and Symptomatic Remission and Community Integration Status in Patients With Schizophrenia (NCT01309373) | Janssen-Cilag, S.A. | 2010-11-01 |
| Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia (NCT01420575) | VA Nebraska Western Iowa Health Care System | 2010-10-01 |